BACKGROUND: Frontotemporal dementia (FTD) has been linked to the microtubule associated protein tau (MAPT) gene region of chromosome 17. However, many chromosome-17 linked FTLDs do not have MAPT mutations or tau protein deposits, but have ubiquitin positive, tau and alpha-synuclein negative inclusions. Mutations in the progranulin (PGRN) gene, located 1.7 Mb from MAPT at 17q21.31, were recently discovered in some of these individuals. The pathologic phenotype in all cases has thus far included ubiquitinated neuronal intranuclear inclusions (NIIs) and neuronal cytoplasmic inclusions (NCIs). METHODS: PGRN mutation analysis was performed in 12 individuals. Informed consent was obtained from next of kin under an IRB-approved protocol. We compared clinical and pathologic findings in those cases with and without PGRN mutations. RESULTS: PGRN mutations were found in four patients, two with clinical FTD and a positive family history, and two with clinical primary progressive aphasia (PPA), one with and one without a family history. All four cases with, and five of eight cases without, PGRN mutations had ubiquitinated NCIs and NIIs. Brains of individuals with PGRN mutations are associated with more frequent frontal NCIs and dystrophic neurites, less frequent dentate gyrus NCIs, and more frequent striatal NIIs than FTLD-U cases without PGRN mutations. CONCLUSION: PGRN mutations at 17q21 may occur in apparently sporadic frontotemporal lobar dementia with ubiquitinated inclusions cases and in cases presenting with either primary progressive aphasia or the behavioral variant of frontotemporal dementia. Some cases without PGRN mutations also have ubiquitinated neuronal intranuclear inclusions. Clinicopathologic differences are observed among individuals with and without PGRN mutations.
BACKGROUND: Frontotemporal dementia (FTD) has been linked to the microtubule associated protein tau (MAPT) gene region of chromosome 17. However, many chromosome-17 linked FTLDs do not have MAPT mutations or tau protein deposits, but have ubiquitin positive, tau and alpha-synuclein negative inclusions. Mutations in the progranulin (PGRN) gene, located 1.7 Mb from MAPT at 17q21.31, were recently discovered in some of these individuals. The pathologic phenotype in all cases has thus far included ubiquitinated neuronal intranuclear inclusions (NIIs) and neuronal cytoplasmic inclusions (NCIs). METHODS:PGRN mutation analysis was performed in 12 individuals. Informed consent was obtained from next of kin under an IRB-approved protocol. We compared clinical and pathologic findings in those cases with and without PGRN mutations. RESULTS:PGRN mutations were found in four patients, two with clinical FTD and a positive family history, and two with clinical primary progressive aphasia (PPA), one with and one without a family history. All four cases with, and five of eight cases without, PGRN mutations had ubiquitinated NCIs and NIIs. Brains of individuals with PGRN mutations are associated with more frequent frontal NCIs and dystrophic neurites, less frequent dentate gyrus NCIs, and more frequent striatal NIIs than FTLD-U cases without PGRN mutations. CONCLUSION:PGRN mutations at 17q21 may occur in apparently sporadic frontotemporal lobar dementia with ubiquitinated inclusions cases and in cases presenting with either primary progressive aphasia or the behavioral variant of frontotemporal dementia. Some cases without PGRN mutations also have ubiquitinated neuronal intranuclear inclusions. Clinicopathologic differences are observed among individuals with and without PGRN mutations.
Authors: D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson Journal: Neurology Date: 1998-12 Impact factor: 9.910
Authors: Duane L Beekly; Erin M Ramos; Gerald van Belle; Woodrow Deitrich; Amber D Clark; Mary E Jacka; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2004 Oct-Dec Impact factor: 2.703
Authors: David S Knopman; Bradley F Boeve; Joseph E Parisi; Dennis W Dickson; Glenn E Smith; Robert J Ivnik; Keith A Josephs; Ronald C Petersen Journal: Ann Neurol Date: 2005-04 Impact factor: 10.422
Authors: D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky Journal: J Neuropsychiatry Clin Neurosci Date: 2000 Impact factor: 2.198
Authors: O Piguet; W S Brooks; G M Halliday; P R Schofield; P M Stanford; J B J Kwok; M-G Spillantini; D Yancopoulou; P J Nestor; G A Broe; J R Hodges Journal: J Neurol Neurosurg Psychiatry Date: 2004-12 Impact factor: 10.154
Authors: Chang-En Yu; Thomas D Bird; Lynn M Bekris; Thomas J Montine; James B Leverenz; Ellen Steinbart; Nichole M Galloway; Howard Feldman; Randall Woltjer; Carol A Miller; Elisabeth McCarty Wood; Murray Grossman; Leo McCluskey; Christopher M Clark; Manuela Neumann; Adrian Danek; Douglas R Galasko; Steven E Arnold; Alice Chen-Plotkin; Anna Karydas; Bruce L Miller; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg; Vivianna M Van Deerlin Journal: Arch Neurol Date: 2010-02
Authors: J D Rohrer; F Geser; J Zhou; E D Gennatas; M Sidhu; J Q Trojanowski; S J Dearmond; B L Miller; W W Seeley Journal: Neurology Date: 2010-12-14 Impact factor: 9.910
Authors: Richard A Armstrong; William Ellis; Ronald L Hamilton; Ian R A Mackenzie; John Hedreen; Marla Gearing; Thomas Montine; Jean-Paul Vonsattel; Elizabeth Head; Andrew P Lieberman; Nigel J Cairns Journal: J Neural Transm (Vienna) Date: 2009-12-10 Impact factor: 3.575
Authors: Michael A Gitcho; Eileen H Bigio; Manjari Mishra; Nancy Johnson; Sandra Weintraub; Marsel Mesulam; Rosa Rademakers; Sumi Chakraverty; Carlos Cruchaga; John C Morris; Alison M Goate; Nigel J Cairns Journal: Acta Neuropathol Date: 2009-07-18 Impact factor: 17.088